- Home
- MIY vs ABEO Comparison
MIY vs ABEO Comparison
Compare MIY & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIY
- ABEO
- Stock Information
- Founded
- MIY 1992
- ABEO 1974
- Country
- MIY United States
- ABEO United States
- Employees
- MIY N/A
- ABEO N/A
- Industry
- MIY Investment Bankers/Brokers/Service
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- MIY Finance
- ABEO Health Care
- Exchange
- MIY Nasdaq
- ABEO Nasdaq
- Market Cap
- MIY 321.2M
- ABEO 332.0M
- IPO Year
- MIY N/A
- ABEO 1980
- Fundamental
- Price
- MIY $11.17
- ABEO $6.83
- Analyst Decision
- MIY
- ABEO Strong Buy
- Analyst Count
- MIY 0
- ABEO 6
- Target Price
- MIY N/A
- ABEO $18.17
- AVG Volume (30 Days)
- MIY 56.8K
- ABEO 702.3K
- Earning Date
- MIY 01-01-0001
- ABEO 08-14-2025
- Dividend Yield
- MIY 3.98%
- ABEO N/A
- EPS Growth
- MIY N/A
- ABEO N/A
- EPS
- MIY N/A
- ABEO 0.99
- Revenue
- MIY N/A
- ABEO $400,000.00
- Revenue This Year
- MIY N/A
- ABEO N/A
- Revenue Next Year
- MIY N/A
- ABEO $339.63
- P/E Ratio
- MIY N/A
- ABEO $6.91
- Revenue Growth
- MIY N/A
- ABEO N/A
- 52 Week Low
- MIY $9.45
- ABEO $3.93
- 52 Week High
- MIY $11.70
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- MIY 58.77
- ABEO 52.71
- Support Level
- MIY $11.07
- ABEO $6.70
- Resistance Level
- MIY $11.24
- ABEO $7.15
- Average True Range (ATR)
- MIY 0.11
- ABEO 0.31
- MACD
- MIY -0.00
- ABEO -0.02
- Stochastic Oscillator
- MIY 73.53
- ABEO 46.62
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.